Market Research Logo

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026

Summary

Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

It is estimated that pharmaceutical sales in the migraine market were approximately US$3.3 Billion throughout the 7MM in 2016. The US contributed to over 70% of these sales, generating about US$2.3 billon, driven mainly by the sale of triptans (around US$1.5 Billion) and Botox (almost US$0.5 Billion). The only triptan to remain patented in the US in 2016 was Pfizer’s Relpax, which consequently is the highest-selling brand within this class.

Global migraine sales are expected to grow to around US$8.5 Billion by 2026, at a Compound Annual Growth Rate (CAGR) of over 10%. The growth will be driven by the launch of several late-stage pipeline products, particularly the calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) erenumab, galcanezumab, fremanezumab, and eptinezumab, developed by Amgen, Eli Lilly, Teva, and Alder respectively.

The major drivers of growth in the migraine market during the forecast period include -

  • The launch and uptake of Eli Lilly’s lasmiditan and Allergan’s ubrogepant, which have novel mechanisms that satisfy unmet needs in the acute treatment market.
  • The launch and uptake of Amgen’s erenumab, Eli Lilly’s galcanezumab, Teva’s fremanezumab, Alder’s eptinezumab, and Allergan’s atogepant, which are the first migraine-specific prophylactic treatments.
  • The high annual cost of therapy for mAbs, which will mean they will generate high sales.
  • A rising prevalence of migraine in the 7MM throughout the forecast period, which will lead to an increase in the diagnosed and treated population and will drive sales.
The report PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026, provides Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following -
  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Pfizer, Amgen, Eli Lilly, Teva, Alder Biopharmaceuticals, Merck & Co, Allergan, Zogenix, RedHill BioPharma, Desitin, Grupe JUSTE, Grunenthal.

Scope
  • Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Migraine: Executive Summary
2.1 Migraine Market Will Grow to $8.7 Billion by 2026
2.2 Companies Often Target the Underserved Migraine Population
2.3 Current Treatments Leave Major Unmet Needs in the Migraine Market
2.4 Market Opportunities for New Entrants
2.5 Late-Stage Pipeline Drugs Will Be a Key Driver in the Migraine Market
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Migraine Classification
4.2 Etiology and Pathophysiology
4.2.1 Etiology
4.2.2 Pathophysiology
4.3 Symptoms
4.3.1 Premonitory Phase
4.3.2 Aura Phase
4.3.3 Headache Phase
4.3.4 Resolution Phase
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Migraine (2016-2026)
5.5.1 Total Prevalent Cases of Migraine
5.5.2 Age-Specific Total Prevalent Cases of Migraine
5.5.3 Sex-Specific Total Prevalent Cases of Migraine
5.5.4 Migraine Cases by Frequency of Occurrences
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.2.3 Episodic Migraine
6.2.4 Chronic Migraine
6.2.5 Non-pharmacological Treatments
6.3 US
6.4 5EU
6.5 Japan
7 Competitive Assessment
7.1 Overview
7.1.1 Maxalt (rizatriptan benzoate)
7.1.2 Relpax (eletriptan hydrobromide)
7.1.3 Treximet (sumatriptan succinate + sodium naproxen)
7.1.4 Sumavel DosePro (sumatriptan succinate)
7.1.5 Rizaport (rizatriptan benzoate)
7.1.6 Onzetra Xsail (sumatriptan succinate)
7.1.7 Other Triptans
7.1.8 Botox (onabotulinum toxin A)
7.1.9 Antidepressants
7.1.10 Anti-epileptics
7.1.11 Other Therapeutic Classes
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Physician Education and Diagnosis
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Effective and Well-Tolerated Prophylactic Treatments
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Clinical Trial Mapping
9.2.1 Clinical Trials by Country and Class
9.3 Promising Drugs in Clinical Development
9.3.1 Lasmiditan (COL-144)
9.3.2 Eptinezumab (ALD-403)
9.3.3 Fremanezumab (TEV-48125)
9.3.4 Galcanezumab (LY2951742)
9.3.5 Erenumab (AMG-334)
9.3.6 Ubrogepant (MK-1602)
9.3.7 Atogepant (AGN241689)
9.3.8 SUD-001
9.4 Promising Drugs in Early-Stage Development
9.5 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 GlaxoSmithKline
10.3.1 Overview
10.3.2 Portfolio Assessment
10.3.3 SWOT Analysis
10.4 Merck & Co.
10.4.1 Overview
10.4.2 Portfolio Assessment
10.4.3 SWOT Analysis
10.5 Pfizer
10.5.1 Overview
10.5.2 Portfolio Assessment
10.5.3 SWOT Analysis
10.6 Allergan
10.6.1 Overview
10.6.2 Portfolio Assessment
10.6.3 SWOT Analysis
10.7 Amgen
10.7.1 Overview
10.7.2 Portfolio Assessment
10.7.3 SWOT Analysis
10.8 Eli Lilly
10.8.1 Overview
10.8.2 Portfolio Assessment
10.8.3 SWOT Analysis
10.9 Alder Biopharmaceuticals
10.9.1 Overview
10.9.2 Portfolio Assessment
10.9.3 SWOT Analysis
10.10 Teva
10.10.1 Overview
10.10.2 Portfolio Assessment
10.10.3 SWOT Analysis
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Migraine Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
1.1 List of Tables
Table 1: Migraine: Key Metrics in the 7MM
Table 2: Migraine Classification from the ICHD-3
Table 3: Diagnostic Criteria for Migraine with Aura
Table 4: Diagnostic Criteria for Migraine without Aura
Table 5: Risk Factors and Comorbidities for Migraine
Table 6: ICHD-3 Diagnostic Criteria for Migraine
Table 7: Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, Select Years 2016-2026
Table 8: Treatment Guidelines for Migraine
Table 9: Most Prescribed Drugs for Migraine by Class in the 7MM, 2016
Table 10: Country Profile - US
Table 11: Country Profile - 5EU
Table 12: Country Profile - Japan
Table 13: Product Profile - Maxalt
Table 14: Maxalt SWOT Analysis, 2017
Table 15: Product Profile - Relpax
Table 16: Relpax Efficacy Clinical Trial Results
Table 17: Percentage of Patients with Headache Response (Mild or No Headache) 2 Hours Following Treatment
Table 18: Relpax SWOT Analysis, 2017
Table 19: Product Profile - Treximet
Table 20: Treximet SWOT Analysis, 2017
Table 21: Product Profile - Sumavel DosePro
Table 22: Sumavel DosePro SWOT Analysis, 2017
Table 23: Product Profile - Rizaport
Table 24: Rizaport SWOT Analysis, 2017
Table 25: Product Profile - Onzetra Xsail
Table 26: Onzetra Xsail SWOT Analysis, 2017
Table 27: Product Profile - Other Triptans
Table 28: Triptan SWOT Analysis, 2017
Table 29: Product Profile - Botox
Table 30: Botox SWOT Analysis, 2017
Table 31: Product Profiles - Antidepressants
Table 32: Antidepressants SWOT Analysis, 2017
Table 33: Product Profiles - Anti-epileptics
Table 34: Anti-epileptics SWOT Analysis, 2017
Table 35: Product Profile - Other Therapeutic Classes
Table 36: Unmet Need and Opportunity in Episodic and Chronic Migraine, 2017
Table 37: Migraine Late-Stage Pipeline, 2017
Table 38: Comparison of Therapeutic Classes in Development for Migraine, 2016-2026
Table 39: Product Profile - Lasmiditan
Table 40: Lasmiditan SWOT Analysis, 2017
Table 41: Product Profile - Eptinezumab (ALD-403)
Table 42: Eptinezumab (ALD-403) SWOT Analysis, 2017
Table 43: Product Profile - Fremanezumab (TEV-48125)
Table 44: Fremanezumab (TEV-48125) SWOT Analysis, 2017
Table 45: Product Profile - Galcanezumab (LY2951742)
Table 46: Product Profile - Erenumab (AMG-334)
Table 47: Erenumab (AMG-334) SWOT Analysis, 2017
Table 48: Product Profile - Ubrogepant (MK-1602)
Table 49: Ubrogepant (MK-1602) SWOT Analysis, 2017
Table 50: Product Profile - Atogepant (AGN241689)
Table 51: Atogepant (AGN241689) SWOT Analysis, 2017
Table 52: Product Profile - SUD-001
Table 53: SUD-001 SWOT Analysis, 2017
Table 54: Drugs in Development for Migraine, 2016
Table 55: Key Companies in the Migraine Market in the 7MM, 2016
Table 56: GlaxoSmithKline Disease Portfolio Assessment, 2017
Table 57: GSK SWOT Analysis, 2017
Table 58: Merck’s Disease Portfolio Assessment, 2017
Table 59: Merck SWOT Analysis, 2017
Table 60: Pfizer’s Disease Portfolio Assessment, 2017
Table 61: Pfizer SWOT Analysis, 2017
Table 62: Allergan’s Disease Portfolio Assessment, 2017
Table 63: Allergan SWOT Analysis, 2017
Table 64: Amgen’s Disease Portfolio Assessment, 2017
Table 65: Amgen SWOT Analysis, 2017
Table 66: Eli Lilly’s Disease Portfolio Assessment, 2017
Table 67: Eli Lilly SWOT Analysis, 2017
Table 68: Alder’s Disease Portfolio Assessment, 2017
Table 69: Alder SWOT Analysis, 2017
Table 70: Teva’s Disease Portfolio Assessment, 2017
Table 71: Teva SWOT Analysis, 2017
Table 72: Migraine Market - Global Drivers and Barriers, 2016-2026
Table 73: Key Events Impacting Sales for Migraine in the US, 2016-2026
Table 74: Migraine Market - Global Drivers and Barriers in the US, 2016-2026
Table 75: Key Events Impacting Sales for Migraine in the 5EU, 2016-2026
Table 76: Migraine Market - Global Drivers and Barriers in the 5EU, 2016-2026
Table 77: Key Events Impacting Sales for Migraine in Japan, 2016-2026
Table 78: Migraine Market - Global Drivers and Barriers in Japan, 2016-2026
Table 79: Key Historical and Projected Launch Dates for Migraine
Table 80: Key Historical and Projected Patent Expiry Dates for Migraine
Table 81: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Migraine in 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents Expected to be Licensed for the Treatment of Migraine During the Forecast Period
Figure 4: Pathophysiology of a Migraine
Figure 5: 7MM, Age-Standardized Total Prevalence of Migraine, Both Sexes, Ages ≥18 Years, 2016
Figure 6: Sources Used and Not Used in Epidemiological Analysis of Migraine Prevalence
Figure 7: Sources Used and Not Used in Epidemiological Analysis of Migraine Frequency
Figure 8: 7MM, Age-Specific Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016
Figure 9: 7MM, Sex-Specific Total Prevalent Cases of Migraine, Ages ≥18 Years, 2016
Figure 10: 7MM, Total Prevalent Migraine Cases by Frequency of Occurrences, Both Sexes, Ages ≥18 Years, 2016
Figure 11: Overview of the Development Pipeline in Migraine. Darkest circle indicates Phase III of development, the lightest circle Phase
Figure 12: Migraine Clinical Trials by Class and Country
Figure 13: Migraine Clinical Trials for Drugs in the Late-Stage Pipeline
Figure 14: A Competitive Assessment of the Late-Stage Pipeline Agents in Development for the Treatment of Migraine for 2016-2026
Figure 15: Clinical and Commercial Positioning of Lasmiditan (COL-144)
Figure 16: Clinical and Commercial Positioning of Eptinezumab (ALD-403)
Figure 17: Clinical and Commercial Positioning of Fremanezumab (TEV-48125)
Figure 18: Clinical and Commercial Positioning of Galcanezumab (LY2951742)
Figure 19: Clinical and Commercial Positioning of Erenumab (AMG-334)
Figure 20: Clinical and Commercial Positioning of Ubrogepant (MK-1602)
Figure 21: Clinical and Commercial Positioning of Atogepant (AGN241689)
Figure 22: Clinical and Commercial Positioning of SUD-001
Figure 23: Global Sales of Branded Products for Migraine by Company in 2016 and 2026
Figure 24: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 25: Global (7MM) Sales Forecast by Country for Migraine in 2016 and 2026
Figure 26: Sales Forecast by Class for Migraine in the US in 2016 and 2026
Figure 27: Sales Forecast by Class for Migraine in the 5EU in 2016 and 2026
Figure 28: Sales Forecast by Class for Migraine in Japan in 2016 and 2026

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report